Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Virus or component thereof
Reexamination Certificate
2003-05-07
2010-10-12
Parkin, Jeffrey S. (Department: 1648)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Virus or component thereof
C424S192100, C536S023720, C435S320100, C435S325000
Reexamination Certificate
active
07811580
ABSTRACT:
Env-CD4 complexes and hybrids are disclosed that expose cryptic epitopes that are important in virus neutralization. Methods of diagnosis, treatment and prevention using the polynucleotides and polypeptides are also provided.
REFERENCES:
patent: 4708871 (1987-11-01), Geysen
patent: 5518723 (1996-05-01), DeVico et al.
patent: 5714316 (1998-02-01), Weiner et al.
patent: 5843454 (1998-12-01), DeVico et al.
patent: 6030772 (2000-02-01), DeVico et al.
patent: WO94/19017 (1994-09-01), None
patent: WO 96/04301 (1996-02-01), None
patent: WO 00/39302 (2000-07-01), None
patent: WO 00/39303 (2000-07-01), None
patent: WO01/30814 (2001-05-01), None
patent: WO 03/020876 (2003-03-01), None
Dash , B., et al., 1994, Deletion of a single N-linked glycosylation site from the transmembrane envelope protein of human immunodeficiency virus type 1 stops cleavage and transport of gp160 preventing env-mediated fusion, J. Gen. Virol. 75(6):1389-1397.
Lu, S., et al., 1998, Immunogenicity of DNA vaccines expresssing human immunodeficiency virus type 1 envelope glycoprotein with and without deletions in the V1/2 and V3 regions, AIDS Res. Human Retrovir. 14(2):151-5.
Gallo, R. C., 2005, The end of the beginning of the drive to an HIV-preventive vaccine: a view from over 20 years, The Lancet 366:1894-1898.
Burton, D. R., et al., 2004, HIV vaccine design and the neutralizing antibody problem, Nat. Immunol. 5(3):233-236.
Barre-Sinoussi et al., “Isolation of a T-Lymphotropic Retrovirus from a Patient at Risk for Acquired Immune Deficiency Syndrome (AIDS),” Science 220, 868-71, 1983.
Arthos et al., “Identification of the Residues in Human CD4 Critical for the Binding of HIV,” Cell 57, 469-81, 1989.
Binley et al., “An Investigation of the High-Avidity Antibody Response to Glycoprotein 120 of Human Immunodeficiency Virus Type 1,” AIDS Res. Hum. Retroviruses 13, 1007-15, 1997.
Bolognesi et al., “HIV Vaccine Development: A Progress Report,” Ann. Int. Med. 8, 603-11, 1994.
Burton & Montefiore, “The antibody response in HIV-1 infection,” AIDS 11 (Suppl. A), 587-98, 1997.
Clackson & Wells, “A Hot Spot of Binding Energy in a Hormone-Receptor Interface,” Science 267, 383-86, 1995.
DeVico et al., “Monoclonal Antibodies Raised Against Covalently Crosslinked of Human Immunodeficiency Type 1 gp120 and CD4 Receptor Identify a Novel Complex-Dependent Epitope on gp120,” Virol. 211, 583-88, 1995.
DeVico et al., “Covalently Crosslinked Complexes of Human Immunodeficiency Virus Type 1 (HIV-1) gp120 and CD4 Receptor Elicit a Neutralizing Immune Response That Includes Antibodies Selective for Primary Virus Isolates,” Virology 218, 258-63, 1996.
D'Sousa et al., “Evaluation of Monoclonal Antibodies to Human Immunodeficiency Virus Type 1 Primary Isolates by Neutralization Assays: Performance Criteria for Selecting Candidate Antibodies for Clinical Trials,” J. Infect. Dis. 75, 1062-75, 1997.
Fiore et al., “The Biological Phenotype of HIV-1 is Usually Retained During and After Sexual Transmission,” Virol. 204, 297-303, 1994.
Gallo et al., “Frequent Detection and Isolation of Cytopathic Retroviruses (HTLV-III) from Patients with AIDS and at Risk for AIDS,” “Serological Analysis of a Subgroup of Human T-Lymphotropic Retroviruses (HTLV-III) Associated with AIDS,” Science 224, 500-03, 1984.
Database PIR Entry A03976 (Entry VCLJA2), May 17, 1985.
Gershoni et al., “HIV Binding to Its Receptor Creates Specific Epitopes for the CD4/gp120 Complex,” FASEB J. 7, 1185-87, 1993.
Geysen et al., “A Priori Delineation of a Peptide Which Mimics a Discontinuous Antigenic Determinant,” Mol. Immunol. 23, 709-15, 1986.
Geysen et al., “Use of peptide synthesis to probe viral antigens for epitopes to a resolution of a single amino acid,” Proc. Natl. Acad. Sci. USA 81, 3998-4002, 1984.
Guyader et al., “Genome Organization and Transactivation of the Human Immunodeficiency Virus Type 2,” Nature 326, 662-69, 1987.
Haynes et al., “Toward an Understanding of the Correlates of Protective Immunity to HIV Infection,” Science 271, 324-28, 1996.
Hu et al., “Protection of Macaques Against SIV Infection by Subunit Vaccines of SIV Envelope Glycoprotein gp160,” Science 255, 456-59, 1992.
Javaherian et al., “Principal neutralizing domain of the human immunodeficiency virus type 1 envelope protein,” Proc. Natl. Acad. Sci. USA 86, 6786-72, 1989.
Kwong et al., “Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody,” Nature 393, 648-59, 1998.
Lacasset et al., “Fusion-Competent Vaccines: Broad Neutralizations of Primary Isolates of HIV,” Science 283, 357-62, 1999.
Leu et al., “Immunogenicity of DNA Vaccines Expressing Human Immunodeficiency Virus Type 1 Envelope Glycoprotein with and without Deletions in the V1/V2 and V3 Regions,” AIDS Res. and Human Retroviruses 14, 151-55, 1998.
Levy et al., “Isolation of Lymphocytopathic Retroviruses from San Francisco Patients with AIDS,” Science 225, 840-42, 1984.
Martin et al., “Rational Design of a CD4 Mimic that Inhibits HIV-1 Entry and Exposes Cryptic Neutralization Epitopes,” Nat. Biotech. 21, 71-76, 2003.
Mascola et al., “Immunization with Envelope Subunit Vaccine Products Elicits Neutralizing Antibodies against Laboratory-Adapted but not Primary Isolates of Human Immunodeficiency Virus Type 1,” J. Infect. Dis. 173, 340-48, 1996.
Matsushita et al., “Characterization of a Human Immunodeficiency Virus Neutralizing Monoclonal Antibody and Mapping of the Neutralizing Epitope,” J. Virol. 62, 2107-44, 1988.
Matthews, “Restricted neutralization of divergent human T-lymphotropic virus type III isolates by antibodies to the major envelope glycoprotein,” Proc. Natl. Acad. Sci. USA 83, 9709-13, 1986.
Montefiori & Evans, “Toward an HIV Type 1 Vaccine that Generates Potent, Broadly Cross-Reactive Neutralizing Antibodies,” AIDS Res. Hum. Retroviruses 15, 689-98, 1999.
Nara et al., “Purified Envelope Glycoproteins from Human Immunodeficiency Virus Type 1 Variants Induce Individual, Type-Specific Neutralizing Antibodies,” J. Virol. 62, 2622-28, 1988.
Palker et al., “Type-specific neutralization of the human immunodeficiency virus with antibodies to env-encoded synthetic peptides,” Proc. Natl. Acad. Sci. USA 85, 1932-36, 1988.
Putney et al., “HTLV-III/LAV-Neutralizing Antibodies to anE. coli-Produced Fragment of the Virus Envelope,” Science 234, 1392-95, 1986.
Ratner et al., “Complete Nucleotide of the AIDS Virus, HTLV-III,” Nature 313, 277-84, 1985.
Rizzuto et al., “A Conserved HIV gp 120 Glycoprotein Structure Involved in Chemokine Receptor Binding,” Science 280, 1949-53, 1998.
Robert-Guroff et al., “HTLV-III-Neutralizing Antibodies in Patients with AIDS and AIDS-Related Complex,” nature 316, 72-73, 1985.
Rushe et al., “Antibodies that inhibit fusion of human immunodeficiency virus-infected cells bind a 24-amino acid sequence of the viral envelope, gp120,” Proc. Natl. Acad. Sci. USA 85, 3198-202, 1988.
Ryu et al., “Structures of an HIV and MHC binding fragment from human CD4 as refined in two crystal lattices,” Structure 2, 59-74, 1994.
Sanchez-Pescador et al., “Nucleotide Sequence and Expression of an AIDS-Associated Retrovirus (ARV-2),” Science 227, 484-92, 1985.
Siegal et al., “Severe Acquired Immunodificiency in Male Homosexuals, Manifested by Chronic Perianal Ulcerative Herpes Simplex Lesions,” N. Engl. J. Med. 305, 1439-44, 1981.
Stamatatos et al., “An Envelope Modification That Renders a Primary, Neutralization-Resistant Clade B Human Immunodeficiency Virus Type 1 Isolate Highly Susceptible to Neutralization by Sera from Other Clades,
Barnett Susan
Srivastava Indresh
Bautista Regina
Lee Helen
Novartis Vaccines & Diagnostics, Inc.
Parkin Jeffrey S.
LandOfFree
Chimeric HIV Env proteins comprising CD4 mini-proteins or... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Chimeric HIV Env proteins comprising CD4 mini-proteins or..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Chimeric HIV Env proteins comprising CD4 mini-proteins or... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4199029